Tislelizumab with etoposide and carboplatin or cisplatin for treating small-cell lung cancer

Tislelizumab in combination with chemotherapy is currently in clinical development for the first-line treatment of extensive stage small-cell lung cancer (SCLC). Extensive stage SCLC is when
cancer cells form in the tissues of the lung and spread beyond the lung to other places in the body.
Symptoms include chest discomfort or pain, a cough that does not go away or gets worse, trouble
breathing and wheezing. Smoking is the biggest risk factor. Standard first-line treatment includes
therapy with anti-programme death-1 (PD-1) antibodies combined with chemotherapy, which
helps immune cells target cancer cells and destroy them. Despite this, extensive stage SCLC is a
challenging disease to treat, and resistance eventually develops relatively quickly in most patients.